AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19382402
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.5% ropivacaine
Trial: 12454761
Drug: Fulvestrant 250
RxNorm normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant 250 mg
Trial: 18327367
Drug: Intraarticular Hylan
RxNorm normalized name: hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular Hylan G‐F 20 treatment for 3 weeks
Trial: 18327367
Drug: Intraarticular Hylan
RxNorm normalized name: hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular Hylan G‐F 20 treatment plus oral vitamin E for 3 weeks
Trial: 18327367
Drug: Intraarticular Na‐hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular Na‐hyaluronate treatment for 5 weeks
Trial: 18327367
Drug: Only arthroscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only arthroscopy treatment
Trial: 6759144
Drug: Alinidine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine 40 mg
Trial: 23782459
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg once daily
Trial: 22574571
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy alone (control group)
Trial: 20222884
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BoNT‐A) treatment with two injections, 6 months apart in the gastrocnemius muscle
Trial: 19908105
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg x kg(‐1)
Trial: 12713551
Drug: 10% glycolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% glycolic acid (pH 3.5), applied once daily, 6 days per week for 4 weeks
Trial: 9387530
Drug: Mifepristone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 50 mg q.12.h. for 2 days
Trial: 31556667
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (pain management course)
Trial: 27075027
Drug: Brief multimodal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief multimodal psychosomatic therapy (BMPT) combined with usual care (UC)
Trial: 19930140
Drug: DTP3 completion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP3 completion among children living in households with monthly income >Rs. 3000 (US$ 50)
Trial: 16230563
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses (100 U and 200 U)
Trial: 12119475
Drug: L-arginine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (12.5 mg.kg(‐1).min(‐1))
Trial: 12523456
Drug: Erythromycin 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 3.0 mg/kg
Trial: 31720722
Drug: Home exercise
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home exercise therapy (7 sessions over 12 weeks)
Trial: 31720722
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (7 sessions over 12 weeks)
Trial: 22282296
Drug: 3.5% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5% lidocaine gel (Group 3)
Trial: 30278569
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of modafinil
Trial: 2716439
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg tenilsetam
Trial: 2716439
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tenilsetam
Trial: 2716439
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg tenilsetam
Trial: 2716439
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg co-dergocrine-mesylate
Trial: 7023894
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg naltrexone administered thrice weekly
Trial: 7023894
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg naltrexone administered thrice weekly
Trial: 30375144
Drug: Medium-dose UVA1
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose UVA1 (40-70 J)
Trial: 27677161
Drug: Nystatin oral
RxNorm normalized name: nystatin Oral Tablet
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nystatin oral suspension (500,000 units, QID)
Trial: 19646801
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (10-month supervised program, 3 times weekly)
Trial: 18298872
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of levobupivacaine and clonidine
Trial: 18298872
Drug: Lumbar plexus
RxNorm normalized name: Bos taurus solar plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar plexus infusion of levobupivacaine and clonidine
Trial: 11488732
Drug: Interstitial radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interstitial radiofrequency therapy (IRFT)
Trial: 3815009
Drug: iohexol, 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol, 350 mg I/ml (Omnipaque, Nycomed UK Ltd)
Trial: 3815009
Drug: iopamidol, 370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopamidol, 370 mg I/ml (Niopam, E. Merck Ltd)
Trial: 31393518
Drug: No endocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endocrine therapy (control group)
Trial: 1681162
Drug: sumatriptan 100
RxNorm normalized name: sumatriptan 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sumatriptan 100 mg
Trial: 2109197
Drug: Etidronate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (400 mg per day)
Trial: 16027128
Drug: Social Behaviour
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Behaviour and Network Therapy (SBNT)
Trial: 11262514
Drug: Exposure and
RxNorm normalized name: Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure and nonexposure-based behavior therapy
Trial: 9555821
Drug: Tretinoin gel
RxNorm normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin gel and cream containing polyolprepolymer‐2
Trial: 9555823
Drug: 0.025% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% tretinoin cream containing polyolprepolymer‐2
Trial: 9555821
Drug: Tretinoin gel
RxNorm normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin gel containing polyolprepolymer‐2 and three tretinoin prototype creams containing polyolprepolymer‐2
Trial: 9555821
Drug: 0.025% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% tretinoin gel formulation containing polyolprepolymer‐2
Trial: 3063051
Drug: Ointments containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointments containing nystatin and/or fusidic acid
Trial: 31553661
Drug: Whole-Brain Radiation
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-Brain Radiation Therapy (WBRT)
Trial: 19001559
Drug: Desvenlafaxine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (100 mg/d)
Trial: 8783954
Drug: Intravenous cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cocktail of pethidine and diazepam
Trial: 1728807
Drug: High-potency multivitamin-mineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-potency multivitamin-mineral supplement
Trial: 6705484
Drug: Intravenous injections
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injections of propranolol
Trial: 6705484
Drug: Intravenous injections
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injections of phentolamine
Trial: 6705484
Drug: Intravenous infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusions of neostigmine
Trial: 20644555
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg PI2 in a minidrink
Trial: 17199056
Drug: Systematic depression
RxNorm normalized name: Nerve depressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic depression treatment program delivered by specialized nurses over 12 months
Trial: 17199056
Drug: Systematic depression
RxNorm normalized name: Nerve depressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic depression treatment program
Trial: 7782594
Drug: Mezlocillin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin (150 mg/kg/12 h)
Trial: 6265082
Drug: Intensive induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive induction chemotherapy (high-dose cyclophosphamide, doxorubicin, and VP-16-213)
Trial: 2224784
Drug: Intensive induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive induction chemotherapy
Trial: 14599261
Drug: Both nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both nicotine patch and bupropion
Trial: 10381299
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg (o.a.d. or b.i.d.)
Trial: 29695589
Drug: high‐dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high‐dose intravenous crenezumab 15 mg/kg every 4 weeks (n = 247)
Trial: 22102056
Drug: β-alanine (BA,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-alanine (BA, 2×800 mg tablets, 3× daily; CarnoSyn®; n=13)
Trial: 22102056
Drug: Placebo (PL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL, 2×800 mg maltodextrin tablets, 3× daily; n=11)
Trial: 3181146
Drug: i.v. etomidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. etomidate (0.3 mg kg‐1)
Trial: 3181146
Drug: thiopentone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thiopentone (4 mg kg‐1)
Trial: 31172828
Drug: Leucine (LEU)
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine (LEU) supplement
Trial: 31172828
Drug: Leucine-enriched BCAA
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine-enriched BCAA (LBCAA) supplement
Trial: 31172828
Drug: Standard BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard BCAA supplement
Trial: 28727924
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy intervention, assessed at 2 weeks for pain reduction.
Trial: 17587710
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin plus aspirin
Trial: 9346426
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline (placebo) administration
Trial: 3518312
Drug: Prednisolone 1.5
RxNorm normalized name: fluprednisolone 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 1.5 mg/kg bw daily, taken in the morning once every three days for 30-45 days
Trial: 3518312
Drug: Prednisolone 30-60
RxNorm normalized name: prednisolone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 30-60 mg daily
Trial: 29444778
Drug: Shexiang Baoxin
RxNorm normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shexiang Baoxin Pill (SBP)
Trial: 26727154
Drug: Home-use laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-use laser device combined with antioxidant facial treatment for 12 weeks followed by 2-week regression period
Trial: 12057615
Drug: Two dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two dose schedule (0 and 6 months) using Twinrix paediatric (360 EL.U HAV antigen/10 microg HBs antigen)
Trial: 12057615
Drug: Three dose
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three dose schedule (0, 1 and 6 months) using adult formulation (720 EL.U HAV antigen/20 microg HBs antigen)
Trial: 7916546
Drug: Somatostatin (SST)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (SST) administered intrathecally and epidurally, mean daily dose 1,252 μg (range 250-3,000 μg), mean duration 11.3 days
Trial: 179223
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with Adriamycin
Trial: 27979753
Drug: HC2 intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HC2 intervention arm CCCs receive implementation of a daily curricula for teachers/parents, children, snack, beverage, physical activity, and screen time policies, and technical assistance with menu modifications.
Trial: 26743856
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg twice a day
Trial: 26743856
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg twice a day (in patients with EGFR mutations)
Trial: 16424116
Drug: Soluble fiber
RxNorm normalized name: Soluble fiber
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble fiber supplement (3 g/d)
Trial: 21696732
Drug: Single-dose fosfomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose fosfomycin trometamol
Trial: 23908551
Drug: Diclofenac 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 4% spray gel
Trial: 21284481
Drug: Exenatide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks)
Trial: 18035519
Drug: Residential cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residential cognitive therapy (RCT)
Trial: 7673657
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg
Trial: 3314645
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg phenoxybenzamine orally
Trial: 10771224
Drug: ICRS implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICRS implantation (Intacs) in unilateral treatment group
Trial: 27043681
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg (once-daily) from admission day until discharge
Trial: 27043681
Drug: No atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No atorvastatin treatment until discharge, atorvastatin started after discharge
Trial: 12848776
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg DEX hydro-bromide preceded at 1 h by quinidine HCl (50 mg)
Trial: 12124547
Drug: Aprotinin (G-2)
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin (G-2)
Trial: 21659848
Drug: 8% pirfenidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% pirfenidone (PFD) gel administered topically 3 times a day during 6 months
Trial: 7241460
Drug: Pressure therapy
RxNorm normalized name: AerobiKA Oscillating Positive Expiratory Pressure Therapy System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure therapy
Trial: 25030
Drug: Diluted diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted diazepam (10 mg diluted to 20-40 ml)
Trial: 21752315
Drug: Deferasirox (DFX)
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox (DFX) treatment at 30-40 mg/kg•d
Trial: 17437788
Drug: Gemcitabine 1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,250 mg/m² on days 1 and 8 plus 70 mg/m² cisplatin or carboplatin (AUC 5) on day 1, repeated every 21 days for 6 cycles
Trial: 16342089
Drug: AZD3582 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3582 375 mg twice a day
Trial: 16342089
Drug: AZD3582 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3582 750 mg twice a day
Trial: 16342089
Drug: Rofecoxib 25
RxNorm normalized name: rofecoxib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 25 mg once a day
Trial: 2525984
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice a day
Trial: 2789926
Drug: BRL 24924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRL 24924 1 mg
Trial: 2789926
Drug: BRL 24924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRL 24924 2 mg
Trial: 4685619
Drug: Isoprenaline inhalation
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline inhalation by bronchial asthmatics
Trial: 20299408
Drug: Fentanyl iontophoretic
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl iontophoretic transdermal system (fentanyl ITS)
Trial: 20299408
Drug: Morphine intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine intravenous (IV) patient-controlled analgesia (PCA)
Trial: 12696399
Drug: WHO/ORS (311
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO/ORS (311 mOsml/L)
Trial: 12696399
Drug: Low-osmolarity solution
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-osmolarity solution (245 mOsm/L)
Trial: 10215673
Drug: levo-alpha-acetylmethadol (LAAM)
RxNorm normalized name: Levo-alpha-acetylmethadol
DrugBank: Levacetylmethadol (DB01227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levo-alpha-acetylmethadol (LAAM) 60 mg/70 kg p.o.
Trial: 10215673
Drug: methadone 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methadone 60 mg/70 kg p.o.
Trial: 10215673
Drug: naloxone 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone 1.0 mg/70 kg i.m. after LAAM
Trial: 8965941
Drug: Dietary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary and laxative treatment, combined with biofeedback training
Trial: 1829515
Drug: Recombinant hepatitis
RxNorm normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hepatitis B vaccine (20 micrograms) in Group A, 4 doses at 0, 1, 2, and 12 months.
Trial: 1829515
Drug: Recombinant hepatitis
RxNorm normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hepatitis B vaccine (10 micrograms) in Group B, 4 doses at 0, 1, 2, and 12 months.
Trial: 6624186
Drug: Verapamil (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (160 mg orally)
Trial: 6624186
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg orally)
Trial: 29299592
Drug: Fluorouracil, 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil, 5% cream (n=468)
Trial: 25950503
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control cream (n=464)
Trial: 10192638
Drug: Methanesulfonyl fluoride
RxNorm normalized name: Methanesulfonyl Fluoride
DrugBank: Methanesulfonyl Fluoride (DB13058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methanesulfonyl fluoride (MSF) at doses of up to 0.18 mg/kg given three times per week for 16 weeks
Trial: 7754477
Drug: Piretanide SR
RxNorm normalized name: piretanide
DrugBank: Piretanide (DB02925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide SR 6 mg/day
Trial: 2271089
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 g coconut oil)
Trial: 15105059
Drug: Levonorgestrel (LNG)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel (LNG) 0.75 mg twice, 12 hours apart
Trial: 27813052
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg 3 times a day, n=20)
Trial: 24008977
Drug: Methotrexate (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (0.05 mg/kg bolus followed by 0.05 mg/kg/h for 6 h)
Trial: 10364087
Drug: Lovastatin therapy
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin therapy (60 mg daily)
Trial: 1992319
Drug: Fluconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (100 mg daily in the first phase, 200 mg daily in the second phase)
Trial: 31521192
Drug: Methotrexate monotherapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate monotherapy after initial treatment with TNF-alpha inhibitor and methotrexate